This newsletter presents you the following key sessions:
1. Talazoparib plus enzalutamide as a first-line treatment in patients with mCRPC, regardless of HRR gene
alteration status
2. Long-term data from CheckMate 9ER confirm superiority of first-line nivolumab plus cabozantinib versus
sunitinib in advanced renal cell carcinoma
3. Pembrolizumab monotherapy for patients with high-risk non-muscle-invasive bladder cancer unresponsive
to bacillus Calmette-Guérin
4. Efficacy and safety outcomes from ARASENS in patients with metastatic hormone-sensitive prostate
cancer by disease volume and disease risk
5. Treatment-free survival outcomes of nivolumab and salvage nivolumab plus ipilimumab in advanced clear
cell renal cell carcinoma